X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

EUROPEAN UROLOGY

期刊標題檢索 EUR UROL 最新評論: The top urology journal, whose position is unshakable. The desk reject... (2024-02-08)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[EUROPEAN UROLOGY]您好,您是該頁面的第 44559 位訪客。

期刊簡介
期刊名稱EUROPEAN UROLOGY EUROPEAN UROLOGY
LetPub Score
9.4
50 ratings
Rate

Reputation
9.9

Influence
9.4

Speed
7.0

期刊簡稱EUR UROL
ISSN0302-2838
E-ISSN1421-993X
h-index187
CiteScore
CiteScoreSJRSNIPCiteScore Rank
43.006.9286.596
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Urology
Q11 / 120

自引率 (2023-2024)2.80%自引率趨勢
掲載範囲
Elsevier is the publisher of European Urology, the official journal of the European Association of Urology.

European Urology publishes peer-reviewed original articles and topical reviews on a wide range of urological problems. Topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, as well as recent advances in techniques, instrumentation, surgery and pediatric urology provide readers with a complete guide to international developments in urology.

Published monthly, European Urology is an important journal for all clinicians and researchers in this field.
官方網站http://www.europeanurology.com/
在線稿件提交https://www.editorialmanager.com/EURUROL
開放訪問No
出版商Elsevier
主題領域医学
出版國/地區NETHERLANDS
發行頻率月刊
創刊年1975
每年文章數93每年文章數趨勢
黃金OA百分比35.55%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
UROLOGY & NEPHROLOGYSCIEQ12/126
索引 (SCI or SCIE)Science Citation Index
Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0302-2838%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Ordinary, 3-6 Week(s)
來自Elsevier的數據: Average 3 Week(s)
競爭力 *來自作者的數據: Very difficult
在線文章發布時間來自Elsevier的數據: Average 21.8 Week(s)
參考鏈接
相關期刊 【EUROPEAN UROLOGY】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Nature Reviews NephrologyH-index: 88

    CiteScore: 39.00
    KIDNEY INTERNATIONALH-index: 250

    CiteScore: 23.30
    Nature Reviews UrologyH-index: 65

    CiteScore: 12.50
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGYH-index: 253

    CiteScore: 22.40
    AMERICAN JOURNAL OF KIDNEY DISEASESH-index: 196

    CiteScore: 20.40
    Clinical Journal of the American Society of NephrologyH-index: 128

    CiteScore: 12.20
    JOURNAL OF UROLOGYH-index: 236

    CiteScore: 11.50
    PROSTATE CANCER AND PROSTATIC DISEASESH-index: 56

    CiteScore: 10.00
    NEPHROLOGY DIALYSIS TRANSPLANTATIONH-index: 155

    CiteScore: 10.10
    AMERICAN JOURNAL OF NEPHROLOGYH-index: 75

    CiteScore: 7.50
    學科內最受檢索的期刊 頁面查看次數
    KIDNEY INTERNATIONAL58737
    RENAL FAILURE56045
    JOURNAL OF UROLOGY51786
    BJU INTERNATIONAL49275
    INTERNATIONAL UROLOGY AND NEPHROLOGY42992
    UROLOGY42053
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY40457
    ASIAN JOURNAL OF ANDROLOGY39279
    PROSTATE38621
    NEPHROLOGY DIALYSIS TRANSPLANTATION38467
  •  

    EUROPEAN UROLOGY EUROPEAN UROLOGY
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    下一頁    末頁  (頁
/2)
  [EUROPEAN UROLOGY] 的評論撰寫評論
作者: Nabi2022


領域: 医学
審稿時間: 3.0 month(s)
結果: 拒稿


撰寫評論

2024-02-08 18:59:06 評論於
The top urology journal, whose position is unshakable. The desk rejection rate by journal editors is 60%, with a requirement of at least 6 reviewers agreeing. Submissions at the end of June are sent for external review within a week. Chinese authors can see the specific progress of the review on WeChat, with new reviewers being invited every 3 days. The efficiency is high and the quality of reviewers is also high. If a reviewer suggests rejection, the editor is likely to suspend the review based on the actual situation and give a direct reject. Overall, the journal has high standards for the quality of articles and the status of authors
(5) 讚! | Nabi2022

作者: 珺俐mm


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-14 10:40:27 評論於
Will I be rejected immediately?
(0) 讚! | 珺俐mm

作者: 仙灵冰蕊


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-05-20 15:39:24 評論於
Review speed: 1.0 | Submission hit rate: 95.0 Experience sharing: 1
(0) 讚! | 仙灵冰蕊

作者: 光明问薇


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-15 20:51:59 評論於
Is this magazine accepting meta submissions on CKD?
(0) 讚! | 光明问薇

作者: 璃月陶宜


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-03-28 18:25:54 評論於
Submission success rate: 75.0
Experience sharing: What does the "statistical code" in the submission guidelines refer to? I don't quite understand what this refers to
(0) 讚! | 璃月陶宜

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 22:31:49 評論於
Research Background, Significance, and Current Development Situation
In recent years, with the rapid development of technology and the increasing demand for intelligent products, research on artificial intelligence has attracted more and more attention. Artificial intelligence has been applied in various fields, such as autonomous driving, medical diagnosis, and personalized recommendation system. However, there are still many challenges and limitations in the development of artificial intelligence, such as the lack of interpretability and robustness of models.

Unsolved Problems or Urgently Need to Solve Problems
One of the unresolved issues in artificial intelligence is the lack of interpretability in deep learning models. The black-box nature of deep learning models makes it difficult for users to understand how the models make predictions, which limits the trust and acceptance of these models in practical applications. Therefore, there is an urgent need to develop interpretable deep learning models that can provide explanations for their predictions.

Research Purpose
The purpose of this study is to develop an interpretable deep learning model that can provide explanations for its predictions. By incorporating human interpretable features and attention mechanisms into the model, we aim to improve the interpretability and accuracy of the model. The results of this study can provide guidance for the development of more transparent and trustworthy deep learning models in practical applications
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 13:27:51 評論於
Important literature, if available, can be referenced to show both sides of the argument
(0) 讚! | 维尔娜菲茨杰拉德

作者: 八坂篷蔚


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-26 17:44:00 評論於
What does the three-part introduction refer to?
(0) 讚! | 八坂篷蔚

作者: 破戒阳平


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-26 17:24:34 評論於
Is the important literature in the results or is it described in the introduction?
(0) 讚! | 破戒阳平

作者: 截手怀梦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-05-05 17:54:04 評論於
Hello, how long is the review period for the submission you made?
(0) 讚! | 截手怀梦

作者: 仲夏运伟


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-03-29 11:23:31 評論於
Hello senior, I would like to ask if the eu you sent is original research? I would like to add you on WeChat. I am a second-year graduate student majoring in urology
(0) 讚! | 仲夏运伟

作者: 黑山培乐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-03-02 12:31:03 評論於
No need for review fees or layout fees
(0) 讚! | 黑山培乐

作者: 碧桃文惠


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-12-20 10:06:48 評論於
How much is the review fee and layout fee?
(0) 讚! | 碧桃文惠

作者: 阳泽baby


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-10-15 12:09:07 評論於
Is this magazine not accepting fully experimental research articles, such as renal studies in the field of biochemistry molecular?
(0) 讚! | 阳泽baby

作者: 中原新洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-09-10 20:03:27 評論於
I don't understand
(0) 讚! | 中原新洁

作者: 松风灵蓝


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-09-01 10:02:18 評論於
Do you accept case reports?
(0) 讚! | 松风灵蓝

作者: 惠泽君


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-06-21 09:45:11 評論於
Does this magazine not accept completely experimental research articles, such as renal studies in biochemistry?
(0) 讚! | 惠泽君

作者: 云来之南


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-03-26 20:06:29 評論於
What is the direction of the writing? phosphoakt 2018-03-02 Post::Research direction: Prostate cancer; CRPC; Acceptance rate: about 50% Review time: about 1 month 2017-11-10 Submit 2017-11-26 Revision needed 2017-12-25 Submit Revision 2018-01-09 Revision needed 2018-02-05 Submit Revision 2018-02-13 Accept
(0) 讚! | 云来之南

作者: 水月庚寅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-03-02 19:12:43 評論於
Review Speed: 1.0 | Submission Hit Rate: 50.0
Experience Sharing: 2017-11-10 Submit 2017-11-26 Revision needed 2017-12-25 Submit Revision 2018-01-09 Revision needed 2018-02-05 Submit Revision 2018-02-13 Accept
(0) 讚! | 水月庚寅

作者: 风啸念烟


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-01-07 11:00:15 評論於
Does anyone know how long the first instance will take?
(0) 讚! | 风啸念烟

作者: 燃木天蓉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-12-30 14:42:47 評論於
Is IF going to reach 20 next year?
(0) 讚! | 燃木天蓉

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-16 20:19:23 評論於
Who can predict how many points there will be next year?
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2013-06-20 15:47:48 評論於
Breakthrough is imminent!
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2013-02-06 12:43:35 評論於
The submission was rejected in just 9 days, with 4 review experts, the requirements were really too high!
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2012-05-01 10:36:26 評論於
Six reviewers, of course, are not easy, and picking out a few loopholes and shortcomings can lead to a lot of problems. Indeed, it's not an exaggeration. But on the other hand, some articles from their own circle aren't that great either, it's just that we're outsiders, so the standards for us are particularly high!
(0) 讚! | 凌霄高洁

首頁    上一頁    1    2    下一頁    末頁  (頁
/2)

開始撰寫 [EUROPEAN UROLOGY] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*